Pfizer Inc. (PFE) and Ranbaxy Laboratories
Ltd. (RBXY) were accused by 11 California pharmacies in a lawsuit of
agreeing to hold back a generic version of the cholesterol-
lowering drug Lipitor in the U.S. and then fixing its price.
As a result of an unlawful agreement with generic-maker Ranbaxy, Pfizer was able to make $18 billion by extending its time as the exclusive U.S. source of Lipitor, the pharmacies claimed in a lawsuit filed Nov. 7 in federal court in San Francisco. In exchange, Pfizer allegedly allowed Ranbaxy to distribute the generic of Lipitor earlier in foreign markets. More Read
As a result of an unlawful agreement with generic-maker Ranbaxy, Pfizer was able to make $18 billion by extending its time as the exclusive U.S. source of Lipitor, the pharmacies claimed in a lawsuit filed Nov. 7 in federal court in San Francisco. In exchange, Pfizer allegedly allowed Ranbaxy to distribute the generic of Lipitor earlier in foreign markets. More Read
No comments:
Post a Comment